EGb761, a Ginkgo Biloba Extract, is Effective against Atherosclerosis In Vitro, and in a Rat Model of Type 2 Diabetes

DSpace/Manakin Repository

EGb761, a Ginkgo Biloba Extract, is Effective against Atherosclerosis In Vitro, and in a Rat Model of Type 2 Diabetes

Citable link to this page

. . . . . .

Title: EGb761, a Ginkgo Biloba Extract, is Effective against Atherosclerosis In Vitro, and in a Rat Model of Type 2 Diabetes
Author: Kang, Seon Mee; Cho, Bong Jun; Shin, Hayley; Jang, Hak Chul; Park, Kyong Soo; Lim, Soo; Yoon, Ji Won; Choi, Sung Hee; Kim, Min; Park, Ho Seon; Cho, Hyun Ju; Kim, Young-Bum; Kim, Hyo Soo

Note: Order does not necessarily reflect citation order of authors.

Citation: Lim, Soo, Ji Won Yoon, Seon Mee Kang, Sung Hee Choi, Bong Jun Cho, Min Kim, Ho Seon Park, et al. 2011. EGb761, a ginkgo biloba extract, is effective against atherosclerosis in vitro, and in a rat model of type 2 diabetes. PLoS ONE 6(6): e20301.
Full Text & Related Files:
Abstract: Background: EGb761, a standardized Ginkgo biloba extract, has antioxidant and antiplatelet aggregation and thus might protect against atherosclerosis. However, molecular and functional properties of EGb761 and its major subcomponents have not been well characterized. We investigated the effect of EGb761 and its major subcomponents (bilobalide, kaemferol, and quercetin) on preventing atherosclerosis in vitro, and in a rat model of type 2 diabetes. Methods and Results: EGb761 (100 and 200 mg/kg) or normal saline (control) were administered to Otsuka Long-Evans Tokushima Fatty rats, an obese insulin-resistant rat model, for 6 weeks (from 3 weeks before to 3 weeks after carotid artery injury). Immunohistochemical staining was performed to investigate cell proliferation and apoptosis in the injured arteries. Cell migration, caspase-3 activity and DNA fragmentation, monocyte adhesion, and ICAM-1/VCAM-1 levels were explored in vitro. Treatment with EGb761 dose-dependently reduced intima-media ratio, proliferation of vascular smooth muscle cells (VSMCs) and induced greater apoptosis than the controls. Proliferation and migration of VSMCs in vitro were also decreased by the treatment of EGb761. Glucose homeostasis and circulating adiponectin levels were improved, and plasma hsCRP concentrations were decreased in the treatment groups. Caspase-3 activity and DNA fragmentation increased while monocyte adhesion and ICAM-1/VCAM-1 levels decreased significantly. Among subcomponents of EGb761, kaemferol and quercetin reduced VSMC migration and increased caspase activity. Conclusions: EGb761 has a protective role in the development of atherosclerosis and is a potential therapeutic agent for preventing atherosclerosis.
Published Version: doi:10.1371/journal.pone.0020301
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107221/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:5360611

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters